TipRanks (Thu, 25-Jun 2:30 PM ET)
VERAXA Biotech (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
TipRanks (Wed, 24-Jun 2:00 PM ET)
Globe Newswire (Wed, 24-Jun 7:00 AM ET)
VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
TipRanks (Mon, 22-Jun 11:30 AM ET)
VERAXA's BiTAC-ADC Technology Shows Tumor-Selective Promise Ahead of BIO Convention
Market Chameleon (Thu, 18-Jun 3:53 AM ET)
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
Veraxa Biotech Holding trades on the NASDAQ stock market under the symbol VRXA.
As of June 26, 2026, VRXA stock price declined to $2.32 with 213,276 million shares trading.
VRXA has a market cap of $328.07 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that VRXA belongs to (by Net Assets): ONEQ.
VRXA support price is $1.54 and resistance is $3.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRXA shares will trade within this expected range on the day.